Published in J Clin Invest on March 08, 2010
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J Clin Invest (2012) 1.45
The Toll-like receptor gene family is integrated into human DNA damage and p53 networks. PLoS Genet (2011) 1.27
The Yin and Yang of Toll-like receptors in cancer. Oncogene (2013) 1.23
TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol (2013) 1.18
Overexpression of TLR3, TLR4, TLR7 and TLR9 in esophageal squamous cell carcinoma. World J Gastroenterol (2011) 1.10
Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer. Oncoimmunology (2012) 1.09
Autophagy facilitates TLR4- and TLR3-triggered migration and invasion of lung cancer cells through the promotion of TRAF6 ubiquitination. Autophagy (2013) 1.04
TIR8/SIGIRR is an Interleukin-1 Receptor/Toll Like Receptor Family Member with Regulatory Functions in Inflammation and Immunity. Front Immunol (2012) 0.99
A new role for microRNAs, as ligands of Toll-like receptors. RNA Biol (2013) 0.96
Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget (2015) 0.89
TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence. EMBO Mol Med (2014) 0.86
Toll-like receptors as novel therapeutic targets for ovarian cancer. ISRN Oncol (2012) 0.86
Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy. PLoS One (2013) 0.85
The expression of Toll-like receptor 8 and its relationship with VEGF and Bcl-2 in cervical cancer. Int J Med Sci (2014) 0.84
Toll-like receptor 7 stimulates production of specialized pro-resolving lipid mediators and promotes resolution of airway inflammation. EMBO Mol Med (2013) 0.83
The therapeutic potential of Toll-like receptor 7 stimulation in asthma. Inflamm Allergy Drug Targets (2012) 0.83
The Role of Toll-Like Receptors in Hematopoietic Malignancies. Front Immunol (2016) 0.83
Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-κB activation and enhances erythroid differentiation arrest. PLoS One (2014) 0.83
Transient receptor potential ankyrin 1 receptor activation in vitro and in vivo by pro-tussive agents: GRC 17536 as a promising anti-tussive therapeutic. PLoS One (2014) 0.80
Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeutic Toll-like receptor 7/8 activation. Oncoimmunology (2012) 0.80
Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma. Protein Cell (2014) 0.80
Silencing of renal DNaseI in murine lupus nephritis imposes exposure of large chromatin fragments and activation of Toll like receptors and the Clec4e. PLoS One (2012) 0.79
TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer. Int J Oncol (2015) 0.79
MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer. Oncogene (2017) 0.79
Dual roles of TLR7 in the lung cancer microenvironment. Oncoimmunology (2015) 0.78
Toll-like receptor-2/6 and Toll-like receptor-9 agonists suppress viral replication but not airway hyperreactivity in guinea pigs. Am J Respir Cell Mol Biol (2013) 0.78
Update in lung cancer and oncological disorders 2010. Am J Respir Crit Care Med (2011) 0.78
Radiation takes its Toll. Cancer Lett (2015) 0.78
High expression of Toll-like receptor 5 correlates with better prognosis in non-small-cell lung cancer: an anti-tumor effect of TLR5 signaling in non-small cell lung cancer. J Cancer Res Clin Oncol (2014) 0.77
Toll Like Receptor 2, 4, and 9 Signaling Promotes Autoregulative Tumor Cell Growth and VEGF/PDGF Expression in Human Pancreatic Cancer. Int J Mol Sci (2016) 0.76
Bacterial immunotherapy of gastrointestinal tumors. Langenbecks Arch Surg (2011) 0.76
Pellino-1 confers chemoresistance in lung cancer cells by upregulating cIAP2 through Lys63-mediated polyubiquitination. Oncotarget (2016) 0.76
Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth. Nat Commun (2017) 0.75
Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab. Mol Cancer Ther (2016) 0.75
Interplay between Inflammation and Stemness in Cancer Cells: The Role of Toll-Like Receptor Signaling. J Immunol Res (2016) 0.75
Reprogramming of TLR7 signaling enhances antitumor NK and cytotoxic T cell responses. Oncoimmunology (2016) 0.75
Immunomodulation by mesenchymal stem cells in treating human autoimmune disease-associated lung fibrosis. Stem Cell Res Ther (2016) 0.75
TLR7 and TLR8 as targets for tumor immunotherapy. Immunotherapy (2010) 0.75
Gonadotropin-mediated chemoresistance: Delineation of molecular pathways and targets. BMC Cancer (2015) 0.75
Decreased expression of TLR7 in gastric cancer tissues and the effects of TLR7 activation on gastric cancer cells. Oncol Lett (2016) 0.75
Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer. Int J Cancer (2017) 0.75
Anti-tumor Activity of Toll-Like Receptor 7 Agonists. Front Pharmacol (2017) 0.75
Inflammation and cancer. Nature (2002) 53.78
Inflammation and cancer: back to Virchow? Lancet (2001) 27.40
Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science (2004) 16.26
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (2004) 14.80
NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol (2005) 13.98
NF-kappaB at the crossroads of life and death. Nat Immunol (2002) 12.98
Cooperation of Toll-like receptor signals in innate immune defence. Nat Rev Immunol (2007) 7.23
Multidisciplinary management of lung cancer. N Engl J Med (2004) 7.13
Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science (2007) 5.54
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest (2007) 5.17
Immune surveillance of tumors. J Clin Invest (2007) 5.04
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med (2007) 4.39
Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 4.30
IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy. J Clin Invest (2005) 4.07
Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. Nature (2007) 4.00
The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med (2008) 3.68
The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev (2007) 3.33
TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res (2006) 3.21
TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev (2006) 3.14
At the crossroads of inflammation and cancer. Cell (2004) 2.96
Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 2.91
Virus infection switches TLR-3-positive human neurons to become strong producers of beta interferon. J Virol (2005) 2.90
TLR3 can directly trigger apoptosis in human cancer cells. J Immunol (2006) 2.79
TLR9 is localized in the endoplasmic reticulum prior to stimulation. J Immunol (2004) 2.68
Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol (2004) 2.63
The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity (2007) 2.44
Cytochrome P450 pharmacogenetics and cancer. Oncogene (2006) 2.38
Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med (2007) 2.20
Response of human pulmonary epithelial cells to lipopolysaccharide involves Toll-like receptor 4 (TLR4)-dependent signaling pathways: evidence for an intracellular compartmentalization of TLR4. J Biol Chem (2003) 2.20
Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest (2004) 1.90
Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer. Cancer Res (2005) 1.77
TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol (2007) 1.72
TLR7 and TLR8 as targets in cancer therapy. Oncogene (2008) 1.72
Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia (2006) 1.67
Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. J Immunol (2007) 1.64
NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo. Blood (2005) 1.56
Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br J Cancer (2004) 1.56
Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res (2007) 1.55
Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res (2007) 1.54
Differential recognition of TLR-dependent microbial ligands in human bronchial epithelial cells. J Immunol (2007) 1.53
Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res (2007) 1.53
Human lung cancer cells express functionally active Toll-like receptor 9. Respir Res (2005) 1.49
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy. Oncologist (2008) 1.47
Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-kappaB-dependent mechanism. J Immunol (2006) 1.40
TLR8-mediated NF-kappaB and JNK activation are TAK1-independent and MEKK3-dependent. J Biol Chem (2006) 1.34
Chlamydia pneumoniae and lung cancer: epidemiologic evidence. Cancer Epidemiol Biomarkers Prev (2005) 1.31
Prior lung disease and risk of lung cancer in a large prospective study. Cancer Causes Control (2004) 1.30
Toll-like receptors, inflammation and cancer. Semin Cancer Biol (2005) 1.29
Exploitation of the Toll-like receptor system in cancer: a doubled-edged sword? Br J Cancer (2006) 1.23
Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. Proc Natl Acad Sci U S A (2007) 1.19
Chlamydia pneumoniae infection and risk of lung cancer. Cancer Epidemiol Biomarkers Prev (2004) 1.18
RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. Clin Exp Metastasis (2006) 1.17
Association between Toll-like receptor gene cluster (TLR6, TLR1, and TLR10) and prostate cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.17
Inflammation as cause for scar cancers of the lung. Integr Cancer Ther (2003) 1.10
An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin Cancer Res (2008) 1.10
Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2006) 1.10
Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med (2004) 1.07
Toll-like receptor signaling stimulates cell cycle entry and progression in fibroblasts. J Biol Chem (2005) 1.05
Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB. J Biol Chem (2003) 1.04
Expression of Toll-like receptor 2 is up-regulated in monocytes from patients with chronic obstructive pulmonary disease. Respir Res (2006) 0.97
Regulation of TLR4-induced IL-6 response in bladder cancer cells by opposing actions of MAPK and PI3K signaling. J Cancer Res Clin Oncol (2008) 0.93
Effects of GM-CSF and M-CSF on tumor progression of lung cancer: roles of MEK1/ERK and AKT/PKB pathways. Int J Mol Med (2006) 0.92
Expression of cytochrome P450 in non-small cell lung cancer. Front Biosci (2008) 0.86
Transcriptional repression of the human fibronectin gene in laryngeal squamous cell carcinoma cells. J Cancer Res Clin Oncol (2001) 0.77
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 12.64
The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer (2012) 10.90
ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics (2009) 8.60
Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol (2011) 5.63
Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res (2011) 5.30
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol (2008) 4.30
In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol (2009) 3.97
Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood (2002) 3.17
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
B cell depletion reduces the development of atherosclerosis in mice. J Exp Med (2010) 2.79
Should we change antibiotic prophylaxis for lung surgery? Postoperative pneumonia is the critical issue. Ann Thorac Surg (2008) 2.71
Prognostic significance of vascular and lymphatic emboli in resected pulmonary adenocarcinoma. Ann Thorac Surg (2013) 2.63
Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis. J Thorac Cardiovasc Surg (2012) 2.57
Catamenial pneumothorax: a prospective study. Chest (2003) 2.46
Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology (2008) 2.39
IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol (2006) 2.39
Coordination of intratumoral immune reaction and human colorectal cancer recurrence. Cancer Res (2009) 2.37
The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res (2007) 2.34
Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. Genome Biol (2008) 2.22
Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. Gastroenterology (2009) 2.01
Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res (2011) 1.91
Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology (2012) 1.88
Telomere dysfunction causes sustained inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 1.87
A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood (2005) 1.86
FcgammaR: The key to optimize therapeutic antibodies? Crit Rev Oncol Hematol (2007) 1.81
Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol (2012) 1.81
Resection of pulmonary metastases from sarcoma: can some patients benefit from a less invasive approach? Ann Thorac Surg (2009) 1.78
Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology (2012) 1.78
Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res (2007) 1.69
Natural immunity to cancer in humans. Curr Opin Immunol (2010) 1.69
Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J (2012) 1.66
Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res (2011) 1.63
Erythropoietin and erythropoietin receptor coexpression is associated with poor survival in stage I non-small cell lung cancer. Clin Cancer Res (2007) 1.59
Pneumothorax recurrence after surgery in women: clinicopathologic characteristics and management. Ann Thorac Surg (2011) 1.58
Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res (2013) 1.58
Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors. PLoS One (2011) 1.55
Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells. Cancer Res (2013) 1.54
Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology (2012) 1.51
Thoracoplasty in the current practice of thoracic surgery: a single-institution 10-year experience. Ann Thorac Surg (2011) 1.51
Impact of cytomorphological detection of circulating tumor cells in patients with liver cancer. Hepatology (2004) 1.48
Prognostic impact of vitamin B6 metabolism in lung cancer. Cell Rep (2012) 1.45
Ocular adnexal lymphoma and Helicobacter pylori gastric infection. Am J Hematol (2010) 1.45
Study of the impact of liver transplantation on the outcome of intestinal grafts in children. Transplantation (2006) 1.44
B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med (2013) 1.43
Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Med (2007) 1.42
Early postoperative prophylactic noninvasive ventilation after major lung resection in COPD patients: a randomized controlled trial. Intensive Care Med (2013) 1.42
Comparison of the rate, location and size of positive surgical margins after laparoscopic and robot-assisted laparoscopic radical prostatectomy. BJU Int (2011) 1.42
Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41
Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer. Am J Respir Crit Care Med (2014) 1.39
Reply to the editor. J Thorac Cardiovasc Surg (2013) 1.39
CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. J Immunol (2005) 1.37
Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology (2013) 1.36
Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res (2013) 1.36
Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology (2013) 1.35
Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2012) 1.34
CD14dimCD16+ and CD14+CD16+ monocytes in obesity and during weight loss: relationships with fat mass and subclinical atherosclerosis. Arterioscler Thromb Vasc Biol (2011) 1.34
Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res (2013) 1.33
Trial watch: Chemotherapy with immunogenic cell death inducers. Oncoimmunology (2012) 1.33
The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J Immunol (2009) 1.32